Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 2/20 | 0.53 |
| ▸ | GABRD | O14764 | 2/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.53 |
| ▸ | GABRE | P78334 | 2/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.53 |
| ▸ | UBE2N | P61088 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463324 | 1.00 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL31463327 | 1.00 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL1585177 | 0.98 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL2037294 | 0.85 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL11632984 | 0.81 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL69747 | 0.80 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1CA12CA1 | |
| SCHEMBL28845162 | 0.80 | MAPK1 (0.43) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL82621 | 0.80 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL29565067 | 0.80 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1GABRPGABRD | |
| SCHEMBL29508473 | 0.80 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094958-A | PARP1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| CN-1501917-A | Compounds useful as insecticides, compounds useful as acaricides, and processes to use and make same | 美国陶氏益农公司 | 2004-06-02 | — | — | CN | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1313704-A2 | COMPOUNDS USEFUL AS INSECTICIDES, COMPOUNDS USEFUL AS ACARICIDES, AND PROCESSES TO USE AND MAKE SAME | Dow AgroSciences LLC (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018339-A2 | COMPOUNDS USEFUL AS INSECTICIDES, COMPOUNDS USEFUL AS ACARICIDES, AND PROCESSES TO USE AND MAKE SAME | DOW AGROSCIENCES LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4260620-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4202901-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4197302-A | HYPOTENSIVE AGENTS, 5-ETHERIFIED, ALSO ESTERS, AMIDES, HYDRAZIDES | CIBA-GEIGY CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4025333-A | Selectively herbicidal 4,6-dibromo-5-hydroxy-2-pyridine carboxamide, salts and esters thereof and methods of preparation and use | THE DOW CHEMICAL COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492183-B2 | Tetrahydroquinazoline derivatives as selective cytotoxic agents | ACIN1, CD4, NFATC1 | MAPK1 741/4885KDM4E 3846/4885L3MBTL1 1393/4885 |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | MAPK1 2144/4885KDM4E 2201/4885L3MBTL1 967/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MAPK1 2422/4885KDM4E 3564/4885L3MBTL1 4704/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | MAPK1 1157/4885KDM4E 2887/4885L3MBTL1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.